XARELTO®: Coronary artery disease (CAD) and peripheral artery disease (PAD) treatment

In the COMPASS trial, the XARELTO® vascular dose* significantly reduced a composite of CV death, MI, and stroke in patients with CAD and/or PAD.†1

The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2

CAD/PAD DOSING Condition-specific dosing

CAD/PAD EFFICACY Significant major CV event risk reduction1

CAD/PAD SAFETY Proven safety profile2

CAD/PAD CLINICAL TRIAL The largest antithrombotic trial to date1

PAD SUBGROUP EFFICACY Limb event rates2

CAD/PAD DUAL PATHWAY INHIBITION Targeting 2 clotting mechanisms at once3

CAD ESC GUIDELINES The only DOAC recommended* in the ESC Guidelines for CAD4

FORMULARY FINDER Coverage for your patients

JANSSEN CAREPATH XARELTO® Savings Program

CAD/PAD Resources

DOSING ACROSS INDICATIONS Condition-specific dosing for XARELTO®

COMPASS REPRINT Eikelboom JW et al. Rivaroxaban with or without aspirin in chronic CV disease

CAD/PAD WELCOME KIT Your patient’s guide to starting treatment

View all resources

*Patients with chronic coronary syndromes (chronic CAD) and in sinus rhythm. Recommended treatment options for dual antithrombotic therapy in combination with aspirin include rivaroxaban, clopidogrel, prasugrel, and ticagrelor.

†Not adjusted for multiplicity.


CAD = coronary artery disease; CV = cardiovascular; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; MI = myocardial infarction; PAD = peripheral artery disease.

CV = cardiovascular; MI = myocardial infarction.
*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trials; 75 mg to 100 mg in practice) once daily.


References: 1. Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. 2. XARELTO® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015;20(6):554-562.4. Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-477.